| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Anesthesia and Critical Care, University of Chicago, Chicago, Illinois 60637
We determined whether flumazenil mimics ischemic preconditioning in chick cardiomyocytes and examined the role of intracellular reactive oxygen species (ROS) and ATP-dependent potassium (KATP) channels in mediating the effect. Chick ventricular myocytes were perfused with a balanced salt solution in a flow-through chamber. Cell viability was quantified using propidium iodide, and ROS generation was assessed using the reduced form of 2',7'-dichlorofluorescin (DCFH). Cells were exposed to 1 h of simulated ischemia and 3 h of reoxygenation. Preconditioning was initiated with 10 min of ischemia followed by 10 min of reoxygenation. Alternatively, flumazenil was added to the perfusate for 10 min and removed 10 min before the start of ischemia. Flumazenil (1 and 10 µM) and preconditioning reduced cell death [54 ± 5%, n = 3; 26 ± 4%, n = 6 (P < 0.05); and 20 ± 2%, n = 6 (P < 0.05), respectively, vs. 57 ± 7%, n = 10, in controls] and increased DCFH oxidation (an index of ROS production) [0.35 ± 0.11, n = 3; 2.64 ± 0.69, n = 8 (P < 0.05); and 2.46 ± 0.52, n = 6 (P < 0.05), respectively, vs. 0.26 ± 0.05, n = 9, in controls]. Protection and increased ROS signals with flumazenil (10 µM) were abolished with the thiol reductant N-(2-mercaptopropionyl)-glycine (2-MPG, 800 µM), an antioxidant (cell death: 2-MPG + flumazenil, 55 ± 12%, n = 6; ROS signals: 2-MPG + flumazenil, 0.11 ± 0.19, n = 6). Treatment with 5-hydroxydecanoate (1 mM), a selective mitochondrial KATP channel antagonist, abolished its protection. These results demonstrate that flumazenil mimics preconditioning to reduce cell death in myocytes. ROS signals with the resultant mitochondrial KATP channel activation are important components of the intracellular signaling pathway of flumazenil.
adenosine 5'-triphosphate-sensitive potassium channels; reactive oxygen species; preconditioning
This article has been cited by other articles:
|
|
 |
|
  K. Inagaki, E. Churchill, and D. Mochly-Rosen Epsilon protein kinase C as a potential therapeutic target for the ischemic heart Cardiovasc Res, May 1, 2006; 70(2): 222 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rosa, J.-P. Maury, J. Terrand, X. Lyon, P. Kucera, L. Kappenberger, and E. Raddatz Ectopic pacing at physiological rate improves postanoxic recovery of the developing heart Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2384 - H2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Kevin, A. K. S. Camara, M. L. Riess, E. Novalija, and D. F. Stowe Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H566 - H574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Zhang, B. C. McPherson, H. Liu, T. S. Baman, P. Rock, and Z. Yao H2O2 opens mitochondrial KATP channels and inhibits GABA receptors via protein kinase C-epsilon in cardiomyocytes Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1395 - H1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, B. C. McPherson, and Z. Yao Preconditioning attenuates apoptosis and necrosis: role of protein kinase C{epsilon} and -{delta} isoforms Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H404 - H410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yao, B. C. McPherson, H. Liu, Z. Shao, C. Li, Y. Qin, T. L. Vanden Hoek, L. B. Becker, and P. T. Schumacker Signal transduction of flumazenil-induced preconditioning in myocytes Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1249 - H1255. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
